There is a quiet shift happening in labs and clinics worldwide: scientists are re-evaluating microarrays as a high-impact and powerful tool to derive critical data to drive the success of translational medicine. Microarrays have proven value in the pathway of translational medicine at all stages, from elucidating key biosignatures of disease, diagnosing disease states, optimizing clinical trial efficacy and outcomes, and answering critical questions of therapeutic treatment direction. More recently, microarrays are frequently combined with other methodologies to synchronize outputs, such as complementing sequencing and proteomic workflows.
In this webinar, Chris Diehnelt, Found & CEO of Robust Diagnostics, will present a real-world example of using peptide arrays to study protein-protein interactions with remarkable resolution.
Tamma Kaysser-Kranich, Head of Development at SCHOTT MINIFAB, will discuss the key aspects of:
Register here: Unleashing the Full Power of Microarrays
Live webinar: 24 February 2026 (on-demand available immediately following live stream)
info@wilam.comAn initiative ofBioMelbourne NetworkLevel 6, HWT Tower40 City RoadSouthbank, VIC 3006
Wilam means home in the Woi-wurrung language of the Wurundjeri People of the Kulin Nation, the Traditional Owners of the lands on which we are based.We respectfully acknowledge the Traditional Custodians of the unceded lands and waters of Victoria, the Bunurong, Eastern Maar, Gunaikurnai, Wadawurrung and Wurundjeri Woi-wurrung peoples, on which we live and work. We pay respect to their Elders past and present. We acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector. We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.